8-K: Carisma Therapeutics and Ocugen's OrthoCellix Announce Merger to Form Regenerative Cell Therapy Powerhouse

Carisma Therapeutics Inc. and OrthoCellix, Inc., a wholly-owned subsidiary of Ocugen, Inc., have entered into a definitive merger agreement to create a Nasdaq-listed company focused on late clinical-stage regenerative cell therapies for orthopedic diseases, primarily NeoCart.

Summary

• Carisma Therapeutics Inc. (Nasdaq: CARM) and OrthoCellix, Inc., a wholly-owned subsidiary of Ocugen, Inc. (Nasdaq: OCGN), have signed a definitive merger agreement.
• The transaction is an all-stock merger, with OrthoCellix merging into a wholly-owned subsidiary of Carisma.
• Upon closing, OrthoCellix's stockholder (Ocugen) and concurrent investment participants are expected to own approximately 90.0% of the combined company on a fully-diluted basis, assuming a $25.0 million concurrent investment.
• Existing Carisma stockholders are expected to own approximately 10.0% of the combined company on a fully-diluted basis.
• The ownership percentages are subject to adjustment based on Carisma's net cash at closing and the actual size of the concurrent investment.
• OrthoCellix is valued at $135.0 million (less any shortfall in the $25.0 million concurrent investment), while Carisma is valued at $15.0 million (subject to net cash adjustment).
• The combined company will focus on OrthoCellix's NeoCart technology for knee articular cartilage defects.
• NeoCart has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and concurrence for a single, confirmatory Phase 3 clinical trial.
• Carisma Therapeutics Inc. is expected to be renamed OrthoCellix, Inc. and trade on the Nasdaq Capital Market under the ticker symbol OCLX.
• Pre-merger Carisma stockholders will receive contingent value rights (CVRs) tied to proceeds from Carisma's legacy assets, including its collaboration and license agreement with ModernaTX, Inc.
• Ocugen has committed to purchase at least $5.0 million of Carisma Common Stock as part of the concurrent investment.
• The transaction is expected to close in the second half of 2025, subject to stockholder approvals from both companies and SEC registration statement effectiveness.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the definitive merger agreement, clear strategic focus on a late-stage asset (NeoCart with RMAT), and a planned concurrent financing to fund key development. The CVRs offer potential upside for legacy shareholders. However, the inherent risks of clinical development and the potential for termination fees introduce some caution, preventing a 'strong buy' sentiment.

Positives

• The merger creates a publicly-traded company focused on a late clinical-stage regenerative cell therapy, NeoCart, which has RMAT designation and a clear path to a single Phase 3 trial.
• The transaction provides value for both Ocugen and Carisma stockholders by unlocking the market potential of NeoCart.
• The concurrent financing of $25.0 million, including a $5.0 million commitment from Ocugen, is expected to fund the combined company through the Phase 3 trial of NeoCart without additional investment from Ocugen.
• Carisma stockholders will receive Contingent Value Rights (CVRs) for potential future proceeds from Carisma's legacy assets, including its ModernaTX, Inc. collaboration, offering a potential upside from previous programs.
• The combined company will be led by a 'well-credentialed management team' from OrthoCellix, suggesting strong leadership for the new entity.

Negatives

• Carisma may be required to pay OrthoCellix a termination fee of $500,000 under specified circumstances.
• OrthoCellix may be required to pay Carisma a termination fee of $750,000 and reimburse up to $500,000 of Carisma's expenses if it fails to secure the $25.0 million concurrent investment commitments by September 15, 2025.
• The CVRs for Carisma's legacy assets are highly speculative, with no assurance that holders will receive any payments, and Parent (combined company) owes no fiduciary duty to CVR holders regarding these assets.
• The valuation of Carisma is subject to adjustment based on its net cash at closing, which could impact the final ownership split for pre-merger Carisma stockholders.
• The transaction is subject to customary closing conditions, including stockholder approvals and regulatory effectiveness, which introduce uncertainty regarding completion.

Risks

• The conditions to the closing or consummation of the Proposed Transactions may not be satisfied, including failure to timely obtain stockholder approvals for the reverse stock split and the merger.
• The proposed concurrent financing may not be completed in a timely manner, or at all.
• Uncertainties exist regarding the timing of the consummation of the Proposed Transactions and the ability of each company to complete them.
• Risks related to Carisma's continued listing on Nasdaq until closing and the combined company's ability to remain listed following the closing.
• Uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the combined company, and other unanticipated spending and costs that could reduce cash resources.
• Risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the Proposed Transactions.
• The occurrence of any event, change, or other circumstance or condition that could give rise to the termination of the merger agreement.
• As a result of adjustments to the exchange ratio, OrthoCellix stockholders and Carisma stockholders could own more or less of the combined company than currently anticipated.
• Risks related to the market price of Carisma's common stock relative to the value suggested by the exchange ratio.
• Uncertainties associated with OrthoCellix's NeoCart portfolio, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in clinical trials.
• Risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance product candidates.
• Uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom.
• Risks related to the failure to realize any value from product candidates being developed and anticipated to be developed due to inherent risks and difficulties in bringing them to market.
• The outcome of any legal proceedings that may be instituted against Carisma, OrthoCellix, or their directors/officers related to the Proposed Transactions.
• The ability of Carisma and OrthoCellix to obtain, maintain, and protect their respective intellectual property rights.
• Competitive responses to the Proposed Transactions.
• Costs of the Proposed Transactions and unexpected costs, charges, or expenses resulting from them.
• Potential adverse reactions or changes to business relationships, operating results, and business generally, resulting from the announcement or completion of the Proposed Transactions.
• Changes in regulatory requirements and government incentives.
• Risks associated with the possible failure to realize, or that it may take longer to realize than expected, certain anticipated benefits of the Proposed Transactions.
• Risk of involvement in litigation, including securities class action litigation, that could divert management attention and harm the combined company's business.

Future Outlook

The combined company will focus on advancing OrthoCellix's NeoCart technology, with plans to initiate a U.S. FDA-endorsed Phase 3 clinical trial for NeoCart by the end of 2025. The concurrent financing is expected to provide sufficient capital to complete this Phase 3 trial. The company aims to bring this 'revolutionary technology' to patients and believes it has 'tremendous potential' to deliver a transformative approach to cartilage repair.

Management Comments

• Dr. Shankar Musunuri (Chairman, Chief Executive Officer, and Co-founder of Ocugen): "We believe merging OrthoCellix with Carisma will allow us to create a publicly-traded company focused on the development of NeoCart and provide value for both Ocugen and Carisma stockholders while unlocking true market potential of NeoCart."
• Dr. Shankar Musunuri: "We believe NeoCart has tremendous potential to deliver a truly transformative approach to cartilage repair, and we’ve established OrthoCellix with dedicated resources to bring this revolutionary technology to the patients who desperately need it."
• Steven Kelly (President and Chief Executive Officer of Carisma): "Carisma evaluated a range of strategic alternatives, and we believe this proposed transaction represents an opportunity to deliver significant value to our stockholders."
• Steven Kelly: "OrthoCellix is strongly positioned with its NeoCart platform, a dedication to developing regenerative cell therapies, and a well-credentialed management team to lead the combined company."

Industry Context

This merger signifies a strategic shift for Carisma Therapeutics, moving away from its previous focus on macrophage engineering for fibrosis and cancer, and instead pivoting to regenerative cell therapies for orthopedic diseases. The acquisition of OrthoCellix's NeoCart, a Phase 3-ready autologous cartilage implant, positions the combined entity in a specialized niche within the growing regenerative medicine market. The RMAT designation for NeoCart suggests a potentially accelerated regulatory pathway, which is a significant factor in the competitive biopharma landscape. The CVRs for Carisma's legacy assets, including the ModernaTX collaboration, indicate an attempt to monetize prior R&D efforts while streamlining the new company's focus.

Comparison to Industry Standards

• The RMAT (Regenerative Medicine Advanced Therapy) designation for NeoCart is comparable to Fast Track, Breakthrough Therapy, and Accelerated Approval designations, indicating FDA's recognition of its potential to address unmet medical needs for serious conditions. This designation aims to expedite development and review, similar to how other advanced therapy companies like bluebird bio (Zynteglo) or Sarepta Therapeutics (Elevidys) have benefited from expedited pathways for their gene therapies.
• The structure of the deal, where the acquired entity's (OrthoCellix) shareholders will own a significant majority (90%) of the combined company, is typical of a reverse merger or 'reverse acquisition' where a private company effectively goes public by merging with a smaller, publicly-traded entity. This is a common strategy for private biotech firms seeking public market access without a traditional IPO, similar to recent reverse mergers seen with companies like Kura Oncology (via a reverse merger with ZetaRx Pharmaceuticals) or Black Diamond Therapeutics (via a reverse merger with Neon Therapeutics).
• The use of Contingent Value Rights (CVRs) to provide pre-merger Carisma stockholders with potential future payments from legacy assets is a standard mechanism in biotech mergers. This allows the acquiring entity to focus on its core pipeline while providing a potential return to legacy shareholders without diluting the new company's immediate value. Examples include the CVRs issued in the acquisition of Alder BioPharmaceuticals by Lundbeck or the acquisition of MyoKardia by Bristol Myers Squibb.

Management Changes

Corporate Governance

Related Party Transactions

• Ocugen, Inc. (Guarantor) is the sole stockholder of OrthoCellix, Inc. and will be the primary recipient of the merger consideration shares.
• Ocugen has committed to purchase at least $5.0 million of Carisma Common Stock as part of the concurrent investment.
• Ocugen contributed the NeoCart Assets to OrthoCellix prior to the merger agreement.
• Ocugen will enter into a Transition Services Agreement and a Manufacturing and Supply Agreement with OrthoCellix prior to closing, leveraging Ocugen's GMP facility.

Stakeholder Impact

• **Shareholders (Carisma):** Will receive shares in the combined company (approximately 10% ownership) and Contingent Value Rights (CVRs) for potential proceeds from Carisma's legacy assets, offering a potential return on prior investments.
• **Shareholders (Ocugen):** As the sole stockholder of OrthoCellix, Ocugen will own approximately 90% of the combined company, potentially unlocking significant value from its NeoCart asset and providing a public vehicle for its development.
• **Employees (Carisma):** The document indicates a change in management, with OrthoCellix's team leading the combined company, suggesting potential changes for Carisma's existing employees.
• **Employees (OrthoCellix/Ocugen):** OrthoCellix's management team will lead the combined company, and Ocugen's GMP facility will support NeoCart development, suggesting continuity and potential growth opportunities.
• **Customers/Patients:** The merger aims to accelerate the development of NeoCart for knee articular cartilage defects, potentially bringing a new regenerative cell therapy to patients in need.
• **Creditors:** The financial terms of the merger, including the concurrent investment and net cash conditions, will impact the combined company's financial health and ability to meet obligations.

Next Steps

• Carisma to prepare and file a registration statement on Form S-4 (including a proxy statement) with the SEC by July 18, 2025.
• Carisma to use reasonable best efforts to cause the Registration Statement to become effective as promptly as practicable.
• Carisma to mail the Proxy Statement to its stockholders as promptly as practicable (no later than two business days) after the Registration Statement is effective.
• OrthoCellix to solicit Company Stockholder Approval within 24 hours after the Registration Statement becomes effective.
• Carisma to call, give notice of, and hold a Parent Stockholder Meeting to obtain Parent Stockholder Approval, to be held as promptly as practicable (no later than 45 days) after the Registration Statement is effective.
• Ocugen to enter into a securities purchase agreement committing to purchase at least $5.0 million of Carisma Common Stock on or before August 1, 2025.
• OrthoCellix and Ocugen to enter into a Transition Services Agreement and a Manufacturing and Supply Agreement, with material terms substantially final by July 11, 2025.
• The combined company plans to initiate a U.S. FDA-endorsed Phase 3 clinical trial for NeoCart by the end of 2025.
• Parent (combined company) to file a registration statement on Form S-8 for the 2025 Equity Incentive Plan and 2025 ESPP promptly after the Effective Time, subject to stockholder approval.

Key Dates

Recommendation

Keywords

Merger, Biotechnology, Regenerative Medicine, Cell Therapy, Orthopedic Diseases, NeoCart, Phase 3 Clinical Trial, RMAT Designation, Reverse Merger, Nasdaq Listing, CARM, OCGN, OCLX, Contingent Value Rights, Capital Raise, Biologics License Application, ModernaTX